{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 138 of 169', 'Appendix 4J: Responsibilities', 'The international coordinating investigator (ICI) is responsible for the approval of the', '(consolidated) clinical trial protocol, including any amendment(s) and the CTR on behalf of', 'all', 'clinical trial investigators and as agreed to in an International Coordinating Investigator', 'Agreement.', 'The national coordinating investigators are responsible for national issues relating to the', 'clinical trial as agreed to in a National Coordinating Investigator Agreement.', 'Each participating investigator is responsible for all aspects of the clinical trial conduct', 'at', 'his/her trial site as agreed to in a Clinical Trial Agreement.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 139 of 169', 'Appendix 5: Hanifin and Rajka (1980) diagnostic criteria for AD', 'From Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;92', '(Suppl):44-47.', 'Major Features: must have 3 or more of the following:', 'Pruritus', 'Typical morphology and distribution:', 'Flexural lichenification or linearity in adults', 'Facial and extensor involvement in infants and children', 'Chronic or chronically-relapsing dermatitis', 'Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)', 'Minor Features: should have 3 or more of the following:', 'Xerosis', 'Ichthyosis, palmar hyperlinearity, or keratosis pilaris', 'Immediate (type 1) skin-test reactivity', 'Raised serum IgE', 'Early age of onset', 'Tendency toward cutaneous infections (especially S. aureus and herpes simplex) or', 'impaired cell-mediated immunity', 'Tendency toward non-specific hand or foot dermatitis', 'Nipple eczema', 'Cheilitis', 'Recurrent conjunctivitis', 'Dennie-Morgan infraorbital fold', 'Keratoconus', 'Anterior subcapsular cataracts', 'Orbital darkening', 'Facial pallor or facial erythema', 'Pityriasis alba', 'Anterior neck folds', 'Itch when sweating', 'Intolerance to wool and lipid solvents', 'Perifollicular accentuation', 'Food intolerance', 'Course influenced by environmental or emotional factors', 'White dermographism or delayed blanch', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 140 of 169', 'Appendix 6: Guidance for anaphylaxis diagnosis', 'Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, Adkinson FN Jr, Bock SA, Branum A, et al. Second', 'symposium on the definition and management of anaphylaxis: Summary report -- Second National', 'Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network symposium. J', 'Allergy Clin Immunol. 2006;117(2):391-397.', 'The National Institute of Allergy and Infectious Diseases (NIAID) and Food Allergy and Anaphylaxis', 'Network Guidance for Anaphylaxis Diagnosis (FAAN) define anaphylaxis as a serious allergic', 'reaction that is rapid in onset and may cause death. They recognize 3 categories of anaphylaxis, with', 'criteria designated to capture from 80% of cases (category 1) to >95% of all cases of anaphylaxis (for', 'all 3 categories).', 'Clinical criteria for diagnosing anaphylaxis', 'Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled:', '1) Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal', 'tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula)', 'AND AT LEAST ONE OF THE FOLLOWING:', 'Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak', 'expiratory flow [PEF], hypoxemia)', 'Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction (eg,', 'hypotonia [collapse], syncope, incontinence)', '2) Two or more of the following that occur rapidly after exposure to a likely allergen for that', 'patient (minutes to several hours):', 'Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen', 'lips-tongue-uvula)', 'Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF,', 'hypoxemia)', 'Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope,', 'incontinence)', 'Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)', '3) Reduced BP after exposure to known allergen for that patient (minutes to several hours):', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}